Dogwood Therapeutics, Inc. (NASDAQ:DWTX – Free Report) – Zacks Small Cap cut their FY2024 earnings per share (EPS) estimates for shares of Dogwood Therapeutics in a report issued on Monday, November 11th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings of ($6.43) per share for the year, down from their previous estimate of ($5.71). The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($5.48) per share.
Dogwood Therapeutics Price Performance
Shares of Dogwood Therapeutics stock opened at $3.46 on Wednesday. Dogwood Therapeutics has a 12 month low of $2.50 and a 12 month high of $23.50.
Dogwood Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Articles
- Five stocks we like better than Dogwood Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Investing in Travel Stocks Benefits
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
